Connection
Naghmehossadat Eshghi to Radiopharmaceuticals
This is a "connection" page, showing publications Naghmehossadat Eshghi has written about Radiopharmaceuticals.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.225 |
|
|
|
-
Eshghi N, Lundeen TF, MacKinnon L, Avery R, Kuo PH. 18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab. Clin Nucl Med. 2018 May; 43(5):e142-e144.
Score: 0.142
-
Eshghi A, Covington MF, Eshghi N, Kuo PH. Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics. Clin Nucl Med. 2022 Jun 01; 47(6):488-495.
Score: 0.047
-
Lundeen TF, Seibyl JP, Covington MF, Eshghi N, Kuo PH. Signs and Artifacts in Amyloid PET. Radiographics. 2018 Nov-Dec; 38(7):2123-2133.
Score: 0.037